All In Biotech

Drug Trial Radar · NCT01828957

Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants

Randomized, Double-blind, Multi-center, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Pneumostem® Versus a Control Group for Treatment of Bronchopulmonary Dysplasia in Premature Infants

Last checked: Nov 20, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

69

Actual

Start

Apr 2013

Primary completion

May 2015

Study completion Aug 2015

Sponsor

Lead sponsor
Medipost Co Ltd.Industry
Sponsor type
Industry
First posted
Apr 11, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 5 days, up to 14 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the efficacy and safety of a single intratracheal administration of Pneumostem® for treatment of Bronchopulmonary Dysplasia (BPD) in high-risk premature infants by comparing Pneumostem-treated group with a control group.

Conditions

  • Bronchopulmonary Dysplasia

Interventions

  • Pneumostem®Biological

  • Normal SalineOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of BPD (moderate to severe) or mortality at 36 weeks PMATime frame: 36 weeks PMA

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.